Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3LOF1)

Drug Name

E 7974 Drug Info

Synonyms

26510-52-1; ethyl 3-oxo-3-(pyridin-2-yl)propanoate; Ethyl picolinoylacetate; ethyl 3-oxo-3-(2-pyridyl)propionate; ethyl 3-oxo-3-pyridin-2-ylpropanoate; ethyl 3-oxo-3-(2-pyridinyl)propanoate; 3-Oxo-3-(2-pyridyl)propionic acid ethyl ester; Ethyl picolinoylacetate, 95%; ethyl 3-oxo-3-(2-pyridyl)propanoate; PubChem11088; ethyl-2-pyridoyl acetate; AC1MC5MX; AC1Q34ND; SCHEMBL601821; CHEMBL2035673; CTK4F8033; DTXSID30371376; MolPort-001-769-152; FQHXWZMJALFSJJ-UHFFFAOYSA-N; ZINC153764; Ethyl picolinoylacetate, AldrichCPR; STL131872

Indication

Disease Entry	ICD 11	Status	REF
Ovarian cancer	2C73	Phase 1	[1]

Cross-matching ID

PubChem CID: 10127315
CAS Number: CAS 610787-07-0
TTD Drug ID: DM3LOF1

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tubulin (TUB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Docetaxel	DMDI269	Advanced cancer	2A00-2F9Z	Approved	[2]
Vinorelbine	DMVXFYE	Advanced cancer	2A00-2F9Z	Approved	[3]
Cabazitaxel	DMPAZHC	Breast cancer	2C60-2C65	Approved	[4]
Colchicine	DM2POTE	Acute gout flare	FA25.0	Approved	[5]
Ixabepilone	DM2OZ3G	Breast cancer	2C60-2C65	Approved	[4]
Eribulin	DM1DX4Q	Breast cancer	2C60-2C65	Approved	[4]
Epothilon	DMITJRU	Ovarian cancer	2C73	Phase 3	[1]
DOLASTATIN-10	DMDUV1S	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
BMS-188797	DML1CK2	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
Indibulin	DM6OFJ8	Advanced sarcoma	2A60-2C35	Phase 2	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tubulin (TUB)	TTML2WA	NOUNIPROTAC	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Emerging drugs for ovarian cancer. Expert Opin Emerg Drugs. 2008 Sep;13(3):523-36.
2	Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
3	Vinca alkaloid and MDR1. Gan To Kagaku Ryoho. 2008 Jul;35(7):1086-9.
4	Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
5	Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74.
6	Synthesis and biological activity of chimeric structures derived from the cytotoxic natural compounds dolastatin 10 and dolastatin 15. J Med Chem. 1998 Apr 23;41(9):1524-30.
7	Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res. 2003 Nov 1;9(14):5187-94.
8	2011 Pipeline of ZioPharm.